Illuminations (a) and attenuation rates (b) of the RHL along the axis of y = 0 m at different angles. by Fei Li (143236)

Subjects:

Illuminations (a) and attenuation rates (b) of the CL along the axis of y = 0 m at different angles. by Fei Li (143236)

Subjects:

The distribution of water footprint levels in China. a, 2005. b, 2010. c, 2015. d, 2022. by Jianqin Ma (20328414)

Subjects:

Cross-plots of (a) the proposed GPR, Ranjbar-Karaml et al. [14], Christaras et al. [52], Feng et al. [16], Gowida et al. [17] models and (b) Khandelwal et al. [13], Brandås et al.... by Fahd Saeed Alakbari (10701871)

Subjects:

COVID19 effect on essential services. by Admas Abera (11821659)

Subjects:

Changes in molecular weight (Mw) of a cement/PA-12 powder mixture at varying temperatures and durations. by Saleh Ahmed Aldahash (16441937)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Subjects:

Comparison of training and predicted values of compound water solubility for different machine learning models: (A) AdaBoost, (B) GBDT, (C) LGBM, (D) RF, (E) XGBoost, (F) RF, and (... by Bin Pan (742525)

Subjects:

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Multi-strain model fitting based on data for influenza A and B cases from the 40th week of 2023 to the 17th week of 2024 in the United States. by Shuanglin Jing (11886368)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: